CytoCares Shanghai

CytoCares is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to developing innovative cell therapies for solid tumors. The company utilizes its proprietary Cyto-Armor platform to engineer armored CAR-T cells designed to survive and function effectively within the hostile tumor microenvironment. Its lead program, CC-001, targets Glypican-3 for the treatment of hepatocellular carcinoma and is currently in early clinical evaluation. CytoCares' broader pipeline includes candidates targeting Claudin 18.2 and Mesothelin for various gastrointestinal and respiratory cancers. By integrating advanced synthetic biology with immunology, the company seeks to provide curative options for patients with refractory solid malignancies.